H.C. Wainwright initiated coverage of Trevi Therapeutics (TRVI) with a Buy rating and $21 price target The company is developing Haduvio for both refractory chronic cough and idiopathic pulmonary fibrosis chronic cough, the analyst tells investors in a research note. The firm views Trevi ‘s RIVER Phase 2a data in refractory chronic cough, released earlier this year, as compelling, and believes the company now has a “meaningfully more derisked path” to approval in RCC than the market gives it credit for.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Promising Phase 2a Results for Trevi Therapeutics’ Haduvio Highlight Potential in RCC and IPF-Cough Markets
- Trevi Therapeutics: Promising Developments and Positive Outlook for Haduvio Program
- Trevi Therapeutics provides additional analysis of Haduvio in chronic cough
- Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Strong Efficacy in RCC and IPF Cough
- Trevi Therapeutics’ Haduvio Phase 2b CORAL Study: A Potential Milestone in IPF Cough Treatment